Physician

Asmita Mishra, M.D.

According to 2025 Medicare claims, Asmita Mishra, M.D. (NPI: 1225225865) practices hematopoietic cell transplantation and cellular therapy in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (NPI: 1306833595; TIN: 593238640) and primary practice location at 33612-9416.

Mishra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 52 traditional Medicare patients, billed 140 HCPCS/CPT codes, and received $11,070 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 362 prescription claims across 58 beneficiaries totaling $1,055,442 in drug costs, led by Rezurock (Belumosudil Mesylate). DME data shows 81 claims. Open Payments data shows 5 records totaling $4,636. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $36,900 to $11,070. In contrast, Part D prescription costs have risen steadily, from $35,145 to $1,055,442. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $0 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	73	404	$36,900
2016	73	413	$35,952
2017	77	299	$25,231
2018	97	316	$26,397
2019	96	339	$28,422
2020	99	308	$24,774
2021	92	341	$31,523
2022	73	187	$16,394
2023	53	96	$8,263
2024	52	140	$11,070

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	24	166	$35,145
2016	34	307	$35,881
2017	42	548	$116,314
2018	62	652	$524,897
2019	72	513	$124,422
2020	75	759	$342,191
2021	79	744	$441,357
2022	62	465	$919,690
2023	59	444	$1,121,595
2024	58	362	$1,055,442

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	26	$5,254
2016	23	98	$12,924
2017	67	194	$30,018
2018	61	299	$47,640
2019	54	320	$39,487
2020	69	357	$40,929
2021	65	339	$23,127
2022	54	260	$11,835
2023	35	268	$8,319
2024	11	81	$1,920

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	26	54	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	28	44	$73
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	11	19	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rezurock	Belumosudil Mesylate	27	810	$684,366
Jakafi	Ruxolitinib Phosphate	21	630	$183,246
Sirolimus	Sirolimus	42	1,651	$7,782
Tacrolimus	Tacrolimus	16	420	$1,130
Acyclovir	Acyclovir	63	3,540	$1,004

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7520	Sirolimus, oral, 1 mg	N	N/R	40	$1,223
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	41	$696

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$276	SANOFI-AVENTIS U.S. LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$4,360	Moffitt Cancer Center
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Asmita Mishra, M.D.?

Tedicare shows public-source Medicare data for Asmita Mishra, M.D. (NPI 1225225865), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Asmita Mishra, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Asmita Mishra, M.D.?

Asmita Mishra, M.D. is linked to H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (billing NPI 1306833595) in the available physician profile data.

Does Asmita Mishra, M.D. have Open Payments data?

Asmita Mishra, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.